Abstract
Objectives Neurologic manifestations of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, COVID-19) infection are common and varied. The objective of this report was to describe clinicopathologic findings of rare acute ascending necrotizing myelitis (ANM) and briefly summarize similar COVID-19–associated longitudinally extended transverse myelitis cases.
Methods We described the clinical presentation, disease course, diagnostic workup, therapeutic measures, and pathologic findings of ANM associated with COVID-19 infection.
Results A 31-year-old previously healthy woman developed a longitudinally extensive lower thoracic myelopathy 3 weeks after COVID-19 infection. The thoracic spinal cord lesion extended to cervical level in 1 week and to the lower medullary level in 2 more weeks. Thoracic laminectomy at T5-T6 level and cord biopsy revealed necrobiotic changes without viral particles or microglial nodules. The clinical deficit stabilized after immunomodulatory and eculizumab therapies.
Discussion COVID-19 infection can cause ANM. It adds to the spectrum of reported cases of COVID-19 –associated encephalitis and myelitis.
PRACTICAL IMPLICATIONS
Consider COVID-19–associated necrotizing myelitis in the differential diagnosis of longitudinally extensive transverse myelopathy. This case adds to the spectrum of necrotizing encephalitis reported in patients with SARS-CoV-2 infection.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, COVID-19) infection frequently causes neurologic dysfunction involving the central and peripheral nervous system and skeletal muscle.1,2 We report clinicopathologic findings of a rare case of ascending necrotizing myelitis (ANM) and briefly summarize similar SARS-CoV-2–associated longitudinally extensive transverse myelitis (LETM) cases.
Case Report
A 31-year-old previously healthy woman presented to the emergency department with a 5-day history of acute ascending weakness, numbness, and autonomic symptoms. Three weeks before the onset of neurologic symptoms, she had a 4-day episode of fever, headache, malaise, and anosmia, and she, her husband, and their son were diagnosed SARS-CoV-2 positive by reverse transcription (RT)-PCR from nasopharyngeal samples. None of them were vaccinated against SARS-CoV-2. An MRI of the spine from an outside facility had shown a patchy enhancing T7-T9 spinal segmental lesion (Figure 1A).
Sagittal T2-weighted images showing patchy intraspinal lesion at T7-T9 level on April 5, 2021 (A) and at T6-T9 level on April 10, 2021 (B). Sagittal T2-weighted images showing lesion extending to C7 cord on April 17, 2021 (C) and to lower medulla on May 4, 2021 (D)
A clinical examination at admission revealed incomplete transverse myelopathy with sensory level at the T10 cord, Medical Research Council (MRC) grades of 3 to −4 strength in her legs, and bladder and bowel dysfunction. An MRI of the spine showed an LETM involving the thoracic cord (Figure 1B). Lumbar puncture showed 19 white blood cells/mm3 (90% lymphocytes), 114 red blood cells/mm3, 124 mg/dL proteins, 56 mg/dL glucose, and negative microbial stains. CSF myelin basic proteins were elevated at 14.7, and oligoclonal bands were absent. CSF SARS-CoV-2 RT-PCR was not performed. Nasopharyngeal sample for SARS-CoV-2 RT-PCR was negative. Serum SARS-CoV-2 immunoglobulin (Ig) G antibodies (IgM and IgG) were positive. The following investigations were normal or unremarkable: CBC and differential, comprehensive metabolic panel, rheumatology panel, meningoencephalitis viral panel, ACE, and complement 3/4; serology of hepatitis B, hepatitis C, herpes simplex virus-11, HIV-2, John Cunningham virus, varicella-zoster virus, aquaporin-4, and myelin oligodendrocyte glycoprotein; and whole-body PET scan, spinal MRA and selective spinal angiogram, brain MRI, and CT scans of the head, thorax, abdomen, and pelvis.
She received a 3-day course of IV methylprednisolone (IVMP) (1 g/d). Over the following 3 days, her deficit progressed to complete paraplegia with sensory level to the T6 cord segment. Plasmapheresis (5 sessions at 40 mL/kg/d on alternate days) was started. During the second week of her hospital stay, weakness and numbness progressed to the left hand and forearm with MRI lesions extending to the C7 cord (Figure 1C). A 3-day course of cyclophosphamide therapy (1 g/d) was added. Given the aggressive course and possibly impending respiratory compromise, she underwent a T5-T6–level laminectomy and spinal cord biopsy. Pathology showed necrobiotic parenchyma with neutrophil, T lymphocyte, and macrophage infiltrates; no microorganisms or microglial nodules were seen (Figure 2). During the fourth week, a repeat MRI showed the cord lesion extending to the caudal medulla (Figure 1D). She received a repeat 5-day course of IVMP and IVIg. In addition, given the progressive lesion despite immunosuppressive therapies and necrobiotic cord histopathology, an empirical trial with weekly IV anticomplement5 (eculizumab) at 600 mg/d for 4 weeks was started. She showed improvement in arm strength and was discharged in a clinically stable state 34 days after hospital admission.
(A) Hematoxylin-eosin stain shows a focus of necrosis with granular, vacuolated background. Inset shows a glial fibrillary acidic protein stain with patches of dark brown gliotic viable areas in the background of amorphous necrotic zones that label light brown. (B) Luxol fast blue stain shows loss of myelin. (C) Neurofilament immunohistochemical study shows fragmentation and loss of axons. (D) CD68 immunohistochemical study shows numerous macrophages in the necrotic areas. (E) CD3 immunohistochemical study shows rare perivascular and parenchymal mature T cell.
At 5-month postdischarge clinic follow-up, her arm strength has improved to MRC grade 5, leg strength to trace at ankles and 2 at hips, and sensory impairment at T7 cord level, and she remained incontinent.
Discussion
Acute ANM is a rare spinal cord disorder. There are a few descriptive cases of ANM associated with neuromyelitis optica, vasculitis, paraneoplastic syndrome, and postradiation myelopathy and as an adverse reaction to immune checkpoint inhibitors in oncologic treatment.3,-,5
COVID-19 infection frequently causes neurologic manifestations.1,2 In our case, the recovery from initial COVID-19 infection, a 3-week interval between infectious illness and ANM, and the lack of pathologic detection of viral particles suggest postinfectious immune-mediated rather than SARS-CoV-2 infectious myelitis. In a recent review of 43 patients with COVID-19–associated acute transverse myelitis (ATM) reported from 21 countries,2 13 cases (31%) experienced localized segmental acute transverse myelitis and 28 cases (69%) showed LETM on MRI scans. Most cases (68%) had a latency of 10 days to 6 weeks, indicating postinfectious complications after COVID-19 infection.2 In another review of 20 cases of ATM,6 the neurologic symptoms followed a mean of 10.3 days of SARS-CoV-2 infection, and the spinal cord lesions spanned a mean of 9.8 vertebral segments, with necrotic-hemorrhagic transformation in 3 cases. CSF PCR for SARS-CoV-2 was negative in all 14 cases examined.6 Outside the neuromyelitis optica spectrum disorder, postinfectious LETM is less common than segmental ATM, and the preponderance of LETM in these series is noteworthy.
A brief review of literature shows 33 reported cases of LETM involving ≥4 spinal cord segments on MRI scans in association with SARS-CoV-2, ranging in age from 7 months to 73 years4,7,-,35 (Table). Two cases were contemporaneous to infective illness16,23 and 18 cases 3–29 days after the infection8,10,12,13,15,17,18,24,-,29,31,-,35 (Table). SARS-CoV-2 RT-PCR was positive in CSF sample in only 1 case18 and in nasopharyngeal swabs in 9 cases.10,16,18,21,23,25,27,29,32 Most patients were treated with immunomodulatory therapies, but prognosis for neurologic recovery was poor (Table).
Summary of Reported Cases of Para SARS-CoV-2 or Post-SARS-CoV-2 Infectious Longitudinally Extensive Transverse Myelitis
Acute encephalitis, including necrotizing encephalitis, has been described with COVID-19 infection.1,36 This is a case of COVID-19–associated ANM with histopathologic confirmation. It adds to the spectrum of encephalomyelitis in COVID-19 infection.
Study Funding
No targeted funding reported.
Disclosure
The authors report no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Appendix Authors
Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
↵* These authors contributed equally to this work.
Submitted and externally peer reviewed. The handling editor was Deputy Editor Kathryn Kvam, MD.
- Received January 6, 2022.
- Accepted April 12, 2022.
- © 2022 American Academy of Neurology
References
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
